We expect that larger doses of TCZ may be necessary to achieve this same type of interference when xenografts include both human endothelial cells and human tumor cells, as in this case the amount of competing IL-6 in the tumor microenvironment will significantly increase. Here, IL6 is linked to neoplasm.